Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In contrast, those treated with GLP-1 RAs showed significant reductions in the risks of mortality, MACEs, and MAKEs during a median follow-up period of 2.3 years
Patients should: Follow the dose escalation schedule to minimise side effects Attend regular follow-up appointments to monitor progress and safety Engage with dietetic support to ensure adequate nutrition whilst reducing calorie intake Combine medication with increased physical activity (aim for 150 minutes moderate-intensity exercise weekly, plus muscle-strengthening activities on at least 2 days per week, as per UK Chief Medical Officers' guidelines) Structured lifestyle programmes : NICE recommends multicomponent interventions including dietary modification, physical activity, and behavioural strategies
Powerful execution
The BBB-crossing ability of liraglutide and lixisenatide has been successfully demonstrated, and they subsequently activate GLP-1 receptors in the brain
US$ 20.63
US$ 22.28
US$ 23.47
US$ 25.69
US$ 25.79
